ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized,
placebo-controlled clinical study.
Author(s): Bozcali E(1), Babalik E, Himmetoglu S, Mihmanli I, Toprak S.
Affiliation(s): Author information:
(1)Department of Cardiology, Baltalimani Bone Diseases Education and Research
Hospital.
Publication date & source: 2013, Coron Artery Dis. , 24(4):328-33
OBJECTIVE: We conducted a clinical trial to examine the effect of ω-3 fatty acids
in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential
impact of ω-3 fatty acids on endothelial function, oxidative stress, and symptom
relief in the CSX.
METHODS AND RESULTS: Eighteen patients with CSX were enrolled according to a
double-blind, randomized, placebo-controlled design. Patients were randomized to
ω-3 fatty acids (1440 mg/day, n=8) or placebo (n=10) for 4 months. We assessed
plasma levels of malondialdehyde (MDA), endothelium-dependent vasodilatation
[flow-mediated dilatation (FMD)], endothelium-independent vasodilatation
[nitroglycerin-mediated dilatation (NMD)], and status of symptom [score with
Seattle Angina Questionnaire (SAQ)] before and after the treatment. After 4
months, patients who were treated with ω-3 fatty acids showed significant
increases in the FMD (from 47±48 to 104±23%, P<0.05) and NMD (from 51±53 to
93±35%, P<0.05) values, and significant decreases in the plasma MDA levels
(4.4±0.86 to 3.35±0.33 µmol/l, P=0.012). SAQ scores were increased significantly
in both groups (from 60±14 to 73±15%, P<0.05 placebo, from 67±10 to 81±9%, P<0.05
treatment group). NMD was correlated negatively with the plasma MDA levels.
CONCLUSION: Four months of therapy with a moderate dose of ω-3 fatty acids
improved the endothelial function and reduced oxidative stress in patients with
CSX.
|